Mr. Young most recently served as Group President and Senior Advisor to the Pfizer CEO prior to his retirement from Pfizer in mid-2022. Mr. Young has been a distinguished member of several boards over the years. He currently serves on the Boards of Johnson Controls International (JCI), Novartis AG (NVTS), and Imbria Pharmaceuticals. Mr. Young previously served on the Boards of Haleon
PLC (HLN), European Federation of Pharmaceutical Industries Associations, The Biotechnology Innovation Organization, and the National Committee on United States-China Relations.
A scientist by training, Mr. Young has almost 35 years of experience, a majority of which were working with Pfizer, where he held several leadership positions across the organization. As Chief Business Officer, Mr. Young led a division that integrated all Strategy, Consulting, Business Development, Business Assessment, Portfolio & Decision Analysis, and the Patient & Health Impact reimbursement and access teams. He also played an integral role in the collaborations that led to the successful development and delivery of the Pfizer-BioNTech COVID-19 vaccine.
Prior to this role, Mr. Young was the Group President of Pfizer Innovative Health, which included six business units: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Vaccines, and Consumer Healthcare. Each business unit focused on developing innovative medicines and vaccines to make a meaningful difference to patients impacted by diseases with significant unmet need.
Mr. Young holds a B.Sc. in Biological Science from Glasgow University and an MBA from Strathclyde Graduate Business School.